Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine , Boston, Massachusetts.
School of Biomedical Sciences and Pharmacy, University of Newcastle , Newcastle, New South Wales , Australia.
Am J Physiol Endocrinol Metab. 2019 Feb 1;316(2):E168-E177. doi: 10.1152/ajpendo.00227.2018. Epub 2018 Dec 21.
Obesity, particularly visceral adiposity, has been linked to mitochondrial dysfunction and increased oxidative stress, which have been suggested as mechanisms of insulin resistance. The mechanism(s) behind this remains incompletely understood. In this study, we hypothesized that mitochondrial complex II dysfunction plays a role in impaired insulin sensitivity in visceral adipose tissue of subjects with obesity. We obtained subcutaneous and visceral adipose tissue biopsies from 43 subjects with obesity (body mass index ≥ 30 kg/m) during planned bariatric surgery. Compared with subcutaneous adipose tissue, visceral adipose tissue exhibited decreased complex II activity, which was restored with the reducing agent dithiothreitol (5 mM) ( P < 0.01). A biotin switch assay identified that cysteine oxidative posttranslational modifications (OPTM) in complex II subunit A (succinate dehydrogenase A) were increased in visceral vs. subcutaneous fat ( P < 0.05). Insulin treatment (100 nM) stimulated complex II activity in subcutaneous fat ( P < 0.05). In contrast, insulin treatment of visceral fat led to a decrease in complex II activity ( P < 0.01), which was restored with addition of the mitochondria-specific oxidant scavenger mito-TEMPO (10 µM). In a cohort of 10 subjects with severe obesity, surgical weight loss decreased OPTM and restored complex II activity, exclusively in the visceral depot. Mitochondrial complex II may be an unrecognized and novel mediator of insulin resistance associated with visceral adiposity. The activity of complex II is improved by weight loss, which may contribute to metabolic improvements associated with bariatric surgery.
肥胖,尤其是内脏脂肪过多,与线粒体功能障碍和氧化应激增加有关,这些被认为是胰岛素抵抗的机制。其背后的机制尚不完全清楚。在这项研究中,我们假设线粒体复合物 II 功能障碍在肥胖患者内脏脂肪组织胰岛素敏感性受损中起作用。我们在计划进行减肥手术期间从 43 名肥胖患者(体重指数≥30kg/m)中获得了皮下和内脏脂肪组织活检。与皮下脂肪组织相比,内脏脂肪组织的复合物 II 活性降低,用还原剂二硫苏糖醇(5mM)处理后可恢复(P<0.01)。生物素转换测定法确定,复合物 II 亚基 A(琥珀酸脱氢酶 A)中的半胱氨酸氧化翻译后修饰(OPTM)在内脏脂肪中比皮下脂肪增加(P<0.05)。胰岛素治疗(100nM)刺激了皮下脂肪中的复合物 II 活性(P<0.05)。相比之下,胰岛素处理内脏脂肪会导致复合物 II 活性下降(P<0.01),加入线粒体特异性氧化剂清除剂 mito-TEMPO(10µM)可恢复其活性。在 10 名严重肥胖患者的队列中,手术减肥降低了 OPTM 并恢复了复合物 II 活性,仅在内脏脂肪中恢复。线粒体复合物 II 可能是与内脏肥胖相关的胰岛素抵抗的一种未被认识的新介质。复合物 II 的活性通过减肥得到改善,这可能有助于减肥手术相关的代谢改善。